<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Eco Animal Health Group Plc — News on 6ix</title>
<link>https://6ix.com/company/eco-animal-health-group-plc</link>
<description>Latest news and press releases for Eco Animal Health Group Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 14 Apr 2026 06:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/eco-animal-health-group-plc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d57d56beedb30cb6f89491.webp</url>
<title>Eco Animal Health Group Plc</title>
<link>https://6ix.com/company/eco-animal-health-group-plc</link>
</image>
<item>
<title>Appointment of Head of Business Development</title>
<link>https://6ix.com/company/eco-animal-health-group-plc/news/appointment-of-head-of-business-development</link>
<guid isPermaLink="true">https://6ix.com/company/eco-animal-health-group-plc/news/appointment-of-head-of-business-development</guid>
<pubDate>Tue, 14 Apr 2026 06:00:00 GMT</pubDate>
<description>ECO Animal Health Group plc announces the appointment of Dr Andrew Winder as Head of Business Development, effective May 11, 2026, to identify strategic growth opportunities for its R&D pipeline. Dr. Winder brings extensive experience from Norbrook Laboratories Ltd, where he secured multiple co-development and distribution agreements and developed a global portfolio strategy that doubled the company's project pipeline. His role will focus on in-licensing partnerships to expand ECO's R&D pipeline</description>
</item>
<item>
<title>Board Change</title>
<link>https://6ix.com/company/eco-animal-health-group-plc/news/board-change-239</link>
<guid isPermaLink="true">https://6ix.com/company/eco-animal-health-group-plc/news/board-change-239</guid>
<pubDate>Tue, 31 Mar 2026 06:00:00 GMT</pubDate>
<description>ECO Animal Health Group plc announces that Independent Non-Executive Director Frank Armstrong will step down following the Annual General Meeting, anticipated in September. Dr. Armstrong is retiring from his position due to his new role as Senior Lay Member (Chair) of the Court of the University of Edinburgh, which he will assume in August 2026. The company has initiated a search for a replacement.
Disclaimer*</description>
</item>
<item>
<title>Full Year Trading Update</title>
<link>https://6ix.com/company/eco-animal-health-group-plc/news/full-year-trading-update-83</link>
<guid isPermaLink="true">https://6ix.com/company/eco-animal-health-group-plc/news/full-year-trading-update-83</guid>
<pubDate>Thu, 19 Mar 2026 07:00:00 GMT</pubDate>
<description>Eco Animal Health Group plc announced a strong full-year trading update for the year ending 31 March 2026, with expected revenue growth of approximately 8% year-on-year, surpassing market expectations of £83.5 million and building on the prior year's £79.6 million. This growth, particularly in North and Latin America, coupled with improved gross margins driven by better pricing and cost of goods, is projected to result in a material increase in adjusted EBITDA over the previous year's £7.3 milli</description>
</item>
<item>
<title>ECOVAXXIN® MG favourable USDA safety assessment</title>
<link>https://6ix.com/company/eco-animal-health-group-plc/news/ecovaxxinr-mg-favourable-usda-safety-assessment</link>
<guid isPermaLink="true">https://6ix.com/company/eco-animal-health-group-plc/news/ecovaxxinr-mg-favourable-usda-safety-assessment</guid>
<pubDate>Wed, 11 Mar 2026 07:00:00 GMT</pubDate>
<description>ECO Animal Health Group plc announced that the United States Department of Agriculture (USDA) has issued a favourable safety assessment for its live poultry vaccine, ECOVAXXIN® MG, targeting Mycoplasma gallisepticum. This positive assessment is a significant step towards obtaining US marketing authorisation, with the final regulatory submission anticipated in late 2027. The vaccine was demonstrated to be safe for target and non-target avian species and showed no reversion or increase in virulenc</description>
</item>
<item>
<title>Block Listing Return</title>
<link>https://6ix.com/company/eco-animal-health-group-plc/news/block-listing-return-42</link>
<guid isPermaLink="true">https://6ix.com/company/eco-animal-health-group-plc/news/block-listing-return-42</guid>
<pubDate>Thu, 05 Mar 2026 16:19:00 GMT</pubDate>
<description>ECO Animal Health Group plc has submitted a block listing return detailing its Executive and Unapproved Share Option Schemes. The company originally listed 1,500,000 ordinary shares on 20 July 2017. Between 12 August 2025 and 12 February 2026, no new securities were issued or allotted under these schemes, leaving a balance of 375,505 unallotted securities. The block scheme itself was not increased during this period.
Disclaimer*</description>
</item>
<item>
<title>EU launch plans for ECOVAXXIN® MS</title>
<link>https://6ix.com/company/eco-animal-health-group-plc/news/eu-launch-plans-for-ecovaxxinr-ms</link>
<guid isPermaLink="true">https://6ix.com/company/eco-animal-health-group-plc/news/eu-launch-plans-for-ecovaxxinr-ms</guid>
<pubDate>Thu, 26 Feb 2026 07:00:00 GMT</pubDate>
<description>ECO Animal Health Group plc is progressing its commercial launch strategy for ECOVAXXIN® MS, a poultry vaccine against Mycoplasma synoviae, across the European Union with a phased rollout planned for 2026 and 2027. The company has secured distribution agreements covering over 220 million layer birds annually in the EU's top seven layer-producing countries, leveraging its existing commercial network for Aivlosin®. ECO expects ECOVAXXIN® MS sales to be immediately margin accretive and contribute m</description>
</item>
<item>
<title>Holding(s) in Company</title>
<link>https://6ix.com/company/eco-animal-health-group-plc/news/holdings-in-company-1221</link>
<guid isPermaLink="true">https://6ix.com/company/eco-animal-health-group-plc/news/holdings-in-company-1221</guid>
<pubDate>Mon, 19 Jan 2026 13:50:00 GMT</pubDate>
<description>Killik & Co LLP has reduced its holding in Eco Animal Health Group PLC, with its voting rights falling from 3.0659% to 2.9578% as of January 16, 2026. This change represents a total of 2,004,230 voting rights. The notification was made on January 19, 2026, and no financial instruments with similar economic effects or direct/indirect voting rights were reported.
Disclaimer*</description>
</item>
<item>
<title>ECOVAXXIN® MS EU marketing authorisation granted</title>
<link>https://6ix.com/company/eco-animal-health-group-plc/news/ecovaxxinr-ms-eu-marketing-authorisation-granted</link>
<guid isPermaLink="true">https://6ix.com/company/eco-animal-health-group-plc/news/ecovaxxinr-ms-eu-marketing-authorisation-granted</guid>
<pubDate>Mon, 22 Dec 2025 07:00:00 GMT</pubDate>
<description>ECO Animal Health Group plc has received EU marketing authorisation for its poultry vaccine ECOVAXXIN® MS, which targets Mycoplasma synoviae infections and aims to reduce air-sac and foot-pad lesions and egg production losses, potentially impacting laying hens by 5-10%. This authorisation was granted over a month earlier than expected, following a positive opinion in November 2025, and represents the first commercial launch from the company's R&D portfolio. ECO Animal Health plans to provide fur</description>
</item>
<item>
<title>Exercise of Share Options by Director</title>
<link>https://6ix.com/company/eco-animal-health-group-plc/news/exercise-of-share-options-by-director-1</link>
<guid isPermaLink="true">https://6ix.com/company/eco-animal-health-group-plc/news/exercise-of-share-options-by-director-1</guid>
<pubDate>Thu, 18 Dec 2025 07:00:00 GMT</pubDate>
<description>Eco Animal Health Group plc announced that Chief Financial Officer Christopher Wilks exercised 4,309 nominal cost share options, which were satisfied by transferring existing ordinary shares from the Employee Benefit Trust, resulting in no new shares being issued. Following this transaction, Mr. Wilks' beneficial shareholding is 178,186 ordinary shares, representing approximately 0.26% of the issued share capital, while the total number of ordinary shares with voting rights remains at 67,759,671</description>
</item>
<item>
<title>Director/PDMR Shareholding</title>
<link>https://6ix.com/company/eco-animal-health-group-plc/news/directorpdmr-shareholding-1099</link>
<guid isPermaLink="true">https://6ix.com/company/eco-animal-health-group-plc/news/directorpdmr-shareholding-1099</guid>
<pubDate>Thu, 04 Dec 2025 14:10:00 GMT</pubDate>
<description>David Hallas, Chief Executive Officer of Eco Animal Health Group plc, purchased 18,348 ordinary shares at 109 pence per share on December 4, 2025. Following this transaction, Mr. Hallas now holds 203,041 ordinary shares, representing approximately 0.29% of the company's issued share capital. This purchase by a key executive may be viewed positively by investors as a sign of confidence in the company's future prospects.
Disclaimer*</description>
</item>
<item>
<title>Results for the six months ended 30 September 2025</title>
<link>https://6ix.com/company/eco-animal-health-group-plc/news/results-for-the-six-months-ended-30-september-2025-7</link>
<guid isPermaLink="true">https://6ix.com/company/eco-animal-health-group-plc/news/results-for-the-six-months-ended-30-september-2025-7</guid>
<pubDate>Mon, 01 Dec 2025 07:00:00 GMT</pubDate>
<description>Eco Animal Health Group plc reported a strong first half with revenue increasing 19% to £39.4 million, driven by significant growth in the USA and Canada (up 30% to £11.2 million) and a recovery in China and Japan (up 48% to £12.1 million). Gross margins improved substantially to 49.6% from 40.3%, leading to adjusted EBITDA of £3.0 million, a considerable increase from £0.4 million in the prior year. The company also received a positive opinion from the EMA for its poultry vaccine ECOVAXXIN® MS,</description>
</item>
<item>
<title>Replacement: Notice of Results</title>
<link>https://6ix.com/company/eco-animal-health-group-plc/news/replacement-notice-of-results-4</link>
<guid isPermaLink="true">https://6ix.com/company/eco-animal-health-group-plc/news/replacement-notice-of-results-4</guid>
<pubDate>Thu, 20 Nov 2025 09:47:00 GMT</pubDate>
<description>Eco Animal Health Group plc will announce its unaudited interim results for the six months ended 30 September 2025 on 1 December 2025, with an analyst briefing scheduled for that morning and a live online investor presentation and Q&A on 2 December 2025. This announcement serves as an amendment to a previous notice, correcting the reporting period.
Disclaimer*</description>
</item>
<item>
<title>EMA Positive Opinion Received for ECOVAXXIN® MS</title>
<link>https://6ix.com/company/eco-animal-health-group-plc/news/ema-positive-opinion-received-for-ecovaxxinr-ms</link>
<guid isPermaLink="true">https://6ix.com/company/eco-animal-health-group-plc/news/ema-positive-opinion-received-for-ecovaxxinr-ms</guid>
<pubDate>Mon, 10 Nov 2025 07:00:00 GMT</pubDate>
<description>ECO Animal Health Group plc has received a Positive Opinion from the European Medicines Agency's Committee for Medicinal Products for Veterinary Use for its poultry vaccine, ECOVAXXIN® MS, against Mycoplasma synoviae infections, which can cause significant economic losses in laying hens. This milestone paves the way for an EU marketing authorisation in the first quarter of 2026 and a commercial launch in the second half of 2026, with the company also planning additional geographic submissions an</description>
</item>
<item>
<title>Head of Global R&D</title>
<link>https://6ix.com/company/eco-animal-health-group-plc/news/head-of-global-randd</link>
<guid isPermaLink="true">https://6ix.com/company/eco-animal-health-group-plc/news/head-of-global-randd</guid>
<pubDate>Wed, 01 Oct 2025 06:00:00 GMT</pubDate>
<description>ECO Animal Health Group PLC announced that Hafid Benchaoui, Head of Global R&D, will be leaving the company to pursue another opportunity. He will remain in his current role until October 21st to facilitate a smooth handover. The company is actively recruiting a replacement and states that its R&D pipeline developments remain on track.
Disclaimer*</description>
</item>
<item>
<title>Result of AGM</title>
<link>https://6ix.com/company/eco-animal-health-group-plc/news/result-of-agm-1142</link>
<guid isPermaLink="true">https://6ix.com/company/eco-animal-health-group-plc/news/result-of-agm-1142</guid>
<pubDate>Thu, 25 Sep 2025 14:15:00 GMT</pubDate>
<description>At the Annual General Meeting of ECO Animal Health Group PLC, all proposed resolutions were duly passed. Resolution 1 received 35,042,909 votes for (99.900%) and 34,924 votes against (0.100%). Resolution 2 saw 34,840,996 votes for (99.330%) and 234,879 votes against (0.670%). Resolutions 3 and 4 had similar outcomes, with approximately 82% in favor and 17.9% against. Resolutions 5, 6, 7 and 8 each received over 34.8 million votes for, representing over 99.2% approval. Resolutions 9, 10, 11, 12 a</description>
</item>
<item>
<title>Appointment of Joint Broker</title>
<link>https://6ix.com/company/eco-animal-health-group-plc/news/appointment-of-joint-broker-152</link>
<guid isPermaLink="true">https://6ix.com/company/eco-animal-health-group-plc/news/appointment-of-joint-broker-152</guid>
<pubDate>Mon, 01 Sep 2025 06:00:00 GMT</pubDate>
<description>ECO Animal Health Group PLC announced the appointment of Panmure Liberum Limited as Joint Broker, effective immediately. Singer Capital Markets will remain the Nominated Adviser and Joint Broker for the company. The company has a portfolio of marketed veterinary products. The company has marketing authorisations in over 70 countries and employs over 200 people worldwide.
Disclaimer*</description>
</item>
<item>
<title>Share Awards to Executive Directors</title>
<link>https://6ix.com/company/eco-animal-health-group-plc/news/share-awards-to-executive-directors</link>
<guid isPermaLink="true">https://6ix.com/company/eco-animal-health-group-plc/news/share-awards-to-executive-directors</guid>
<pubDate>Fri, 29 Aug 2025 06:00:00 GMT</pubDate>
<description>On August 28, 2025, Eco Animal Health Group PLC granted nominal cost conditional share options to Executive Directors under the Long Term Incentive Plan (LTIP) covering 374,318 ordinary shares, representing approximately 0.55% of the company's issued share capital. The CEO, David Hallas, received 215,106 share awards, while the CFO, Chris Wilks, received 159,212. Additionally, under the Deferred Bonus Plan (DBS), Hallas received options over 35,472 ordinary shares and Wilks received options over</description>
</item>
<item>
<title>Posting of Annual Report and Notice of AGM</title>
<link>https://6ix.com/company/eco-animal-health-group-plc/news/posting-of-annual-report-and-notice-of-agm-196</link>
<guid isPermaLink="true">https://6ix.com/company/eco-animal-health-group-plc/news/posting-of-annual-report-and-notice-of-agm-196</guid>
<pubDate>Thu, 28 Aug 2025 06:48:00 GMT</pubDate>
<description>ECO Animal Health Group PLC announced the posting of its Annual Report and Accounts for the year ended 31 March 2025, along with the Notice of Annual General Meeting (AGM) and Form of Proxy, to shareholders who elected to receive hard copies. The Annual Report, Notice of AGM, and Form of Proxy are also available on the company's website. The AGM will be held on Thursday 25 September 2025 at 09.00am at The Grange, 100 High Street, London, N14 6BN.
Disclaimer*</description>
</item>
<item>
<title>Result of General Meeting</title>
<link>https://6ix.com/company/eco-animal-health-group-plc/news/result-of-general-meeting-361</link>
<guid isPermaLink="true">https://6ix.com/company/eco-animal-health-group-plc/news/result-of-general-meeting-361</guid>
<pubDate>Thu, 21 Aug 2025 11:29:00 GMT</pubDate>
<description>Eco Animal Health Group plc (AIM: EAH) announced that a general meeting resulted in the approval of a special resolution authorizing the trustees of the ECO Animal Health Group Employee Benefit Trust to begin limited on-market repurchases of the company's ordinary shares (5 pence each). Voting results are available on the company's website.
Disclaimer*</description>
</item>
<item>
<title>Results for the year ended 31 March 2025</title>
<link>https://6ix.com/company/eco-animal-health-group-plc/news/results-for-the-year-ended-31-march-2025-9</link>
<guid isPermaLink="true">https://6ix.com/company/eco-animal-health-group-plc/news/results-for-the-year-ended-31-march-2025-9</guid>
<pubDate>Mon, 14 Jul 2025 06:00:00 GMT</pubDate>
<description>Results for the year ended 31 March 2025.</description>
</item>
</channel>
</rss>